Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Coverage Of Tumor Assays Should Be Monitored - MCAC Panel

This article was originally published in The Gray Sheet

Executive Summary

Human tumor assay systems demonstrate clinical utility for certain patients and hold promise as a tool for treating a broad range of cancers, the Laboratory and Diagnostic Services Panel of the Medicare Coverage Advisory Committee agreed at its Nov. 15-16 meeting in Baltimore.
Advertisement

Related Content

MCAC Panel Recommends Medicare Coverage For Stem Cell Therapy
MCAC Panel Recommends Medicare Coverage For Stem Cell Therapy
Medicare Coverage Advisory Committee Charter Calls For 12 Industry Reps
SPECT COINCIDENCE DETECTION EQUIPMENT ADDED TO FDG PET MEDICARE COVERAGE DECISION FOLLOWING ADAC PRESENTATION TO HCFA; INTERIM COVERAGE EFFECTIVE JAN. 1
Advertisement
UsernamePublicRestriction

Register

MT012614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel